Benzinga · Nov 19, 2026
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
NASDAQ · ONCY
Healthcare · Biotechnology
$0.35
Down-$0.04 (-10.37%)
Updated Nov 21, 2026, 5:20 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ONCY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
ONCY closed at $0.35 after 21 trading sessions, down 30.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $0.38 | $0.3885 | $0.34 | $0.3501 | 1.11M |
| Nov 19, 2026 | $0.4434 | $0.46 | $0.39 | $0.3906 | 1.7M |
| Nov 18, 2026 | $0.3899 | $0.4454 | $0.3765 | $0.4403 | 2.19M |
| Nov 17, 2026 | $0.3336 | $0.3933 | $0.3334 | $0.3825 | 1.59M |
| Nov 16, 2026 | $0.371 | $0.3763 | $0.337 | $0.3399 | 1.33M |
| Nov 13, 2026 | $0.3834 | $0.3896 | $0.3363 | $0.37 | 1.26M |
| Nov 12, 2026 | $0.4128 | $0.42 | $0.3682 | $0.372 | 818.34K |
| Nov 11, 2026 | $0.398 | $0.4191 | $0.3669 | $0.4116 | 1.5M |
| Nov 10, 2026 | $0.4113 | $0.4176 | $0.3815 | $0.3818 | 545.2K |
| Nov 9, 2026 | $0.45 | $0.46 | $0.3829 | $0.4077 | 1.14M |
| Nov 6, 2026 | $0.4551 | $0.461 | $0.4282 | $0.4394 | 516.95K |
| Nov 5, 2026 | $0.43 | $0.457 | $0.3841 | $0.4488 | 2.86M |
| Nov 4, 2026 | $0.4101 | $0.4442 | $0.3949 | $0.4248 | 873.74K |
| Nov 3, 2026 | $0.40 | $0.4072 | $0.3816 | $0.39 | 554.44K |
| Nov 2, 2026 | $0.4237 | $0.4255 | $0.394 | $0.40 | 847.95K |
| Oct 30, 2026 | $0.4207 | $0.4299 | $0.405 | $0.4254 | 764.33K |
| Oct 29, 2026 | $0.44 | $0.45 | $0.425 | $0.4277 | 607.28K |
| Oct 28, 2026 | $0.46 | $0.4631 | $0.43 | $0.4416 | 2.19M |
| Oct 27, 2026 | $0.4703 | $0.4998 | $0.4601 | $0.4623 | 859.33K |
| Oct 26, 2026 | $0.51 | $0.52 | $0.47 | $0.4732 | 711.69K |
| Oct 23, 2026 | $0.505 | $0.5077 | $0.49 | $0.5023 | 376.01K |
The latest Smart Investors Daily articles mentioning ONCY.
Company
Market Activity
Research & News
ONCY research
Company profile and research snapshot.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2025 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Aug 11, 2025 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Aug 8, 2025 | JONES TRADING | Hold | — |
| Aug 7, 2025 | JONES TRADING | Hold | — |
| Jul 9, 2025 | LEEDE JONES GABLE | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 19, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
Yahoo · Nov 16, 2026
By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Clinical Supply Agreement with Coherus for SCAC Trial On November 11, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced a clinical supply agreement with Coherus Oncology, Inc. in which Coherus will supply LOQTORZI ® (toripalimab-tpzi) a next-generation PD-1 inhibitor, for use in a planned clinical study in
Yahoo · Nov 13, 2026
Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance Study may represent a first step toward evaluating the combination more broadly across HPV-associated cancers SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, announced today that it has entered into a clinic
Yahoo · Nov 9, 2026
Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancerSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology (“ASH”) Annual Meeting and Ex
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ONCY.